Hyperglycemia and insulin resistance in COVID-19 versus non-COVID critical illness: Are they really different?

Langouche, Lies; Van den Berghe, Greet; Gunst, Jan

Langouche, Lies; Van den Berghe, Greet; Gunst, Jan.

Langouche L; Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Van den Berghe G; Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Gunst J; Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium. jan.gunst@kuleuven.be.

Crit Care ; 25(1): 437, 2021 12 17.

Article in English | MEDLINE | ID: covidwho-1582029

Subject(s)

COVID-19; Hyperglycemia; Insulin Resistance; COVID-19/complications; COVID-19/diagnosis; Critical Illness; Humans; SARS-CoV-2

Keywords

COVID-19; Diabetes; Hyperglycemia; Insulin

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Insulin Resistance / COVID-19 / Hyperglycemia Type of study: Diagnostic study Topics: Long Covid Limits: Humans Language: English Journal: Crit Care Year: 2021 Document Type: Article Affiliation country: S13054-021-03861-6

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google